Nelfinavir (NFV)

population PK/PD

Nelfinavir is shown to block S fusion to cellular membrane, which is a phenomenon similar to virus (such as SARS-CoV-2) entry requiring the presence of ACE2, at µM concentrations. It was also found to have low binding energy for COVID-19 protease targets and very high affinity at a single binding site. Recently published in vitro studies also showed that nelfinavir exhibits anti-SARS-CoV-2 activities at low IC50/EC50 values (ranging from 0.77 to 2.89 µM) in Vero E6/TMPRSS2 cells.

These data supported the idea that nelfinavir might be further investigated as a potential choice to use for the treatment of COVID-19.

The in silico workbench is intended for use by researchers to assist with clinical trial design and for exploratory and educational purposes. It is NOT intended for use in the diagnosis, cure, mitigation or treatment of any disease. Data provided are not intended to suggest that any product and/or dosing regimen are safe and effective for any use and are for informational purposes only. Please see Terms and Conditions for additional information.